D Gurwitz

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. ncbi request reprint A call for the creation of personalized medicine databases
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Nat Rev Drug Discov 5:23-6. 2006
  2. ncbi request reprint [Pharmacogenetics: towards personalized medicine]
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Harefuah 144:711-6, 750. 2005
  3. ncbi request reprint 'Drug reactions, enzymes, and biochemical genetics': 50 years later
    David Gurwitz
    Pharmacogenomics 8:1479-84. 2007
  4. pmc Ancestry in translational genomic medicine: handle with care
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Genome Med 1:24. 2009
  5. ncbi request reprint Personalized medicine Europe: health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19-21, 2005
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Hum Genet 14:376-80. 2006
  6. ncbi request reprint Do endogenous cannabinoids contribute to HIV-mediated immune failure?
    D Gurwitz
    National Laboratory for the Genetics of Israeli Populations, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Mol Med Today 4:196-200. 1998
  7. pmc Personal genomics services: whose genomes?
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Hum Genet 17:883-9. 2009
  8. doi request reprint Pharmacogenomics: the importance of accurate phenotypes
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978 Israel
    Pharmacogenomics 11:469-70. 2010
  9. doi request reprint Pharmacogenetics education: 10 years of experience at Tel Aviv University
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Pharmacogenomics 11:647-9. 2010
  10. pmc Personalized participatory medicine: sharing knowledge and uncertainty
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Genome Med 3:69. 2011

Collaborators

Detail Information

Publications29

  1. ncbi request reprint A call for the creation of personalized medicine databases
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Nat Rev Drug Discov 5:23-6. 2006
    ..Here, we discuss the rationale for such personalized medicine databases, and the key practical and ethical issues that need to be addressed in their establishment...
  2. ncbi request reprint [Pharmacogenetics: towards personalized medicine]
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Harefuah 144:711-6, 750. 2005
    ..Education of health professionals in pharmacogenetics as part of their pharmacology curricula, and explaining its potential to the general public, would be indispensable for the success of personalized medicine...
  3. ncbi request reprint 'Drug reactions, enzymes, and biochemical genetics': 50 years later
    David Gurwitz
    Pharmacogenomics 8:1479-84. 2007
  4. pmc Ancestry in translational genomic medicine: handle with care
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Genome Med 1:24. 2009
    ..Translational genomic medicine will allow for individualized clinical decision making - doing away with the use of race, ethnicity or ancestry as a proxy...
  5. ncbi request reprint Personalized medicine Europe: health, genes and society: Tel-Aviv University, Tel-Aviv, Israel, June 19-21, 2005
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Hum Genet 14:376-80. 2006
  6. ncbi request reprint Do endogenous cannabinoids contribute to HIV-mediated immune failure?
    D Gurwitz
    National Laboratory for the Genetics of Israeli Populations, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Mol Med Today 4:196-200. 1998
    ..Here, we propose the hypothesis that endogenous cannabinoids, derived mostly from macrophages, might participate in the general failure of the immune system in HIV-infected individuals...
  7. pmc Personal genomics services: whose genomes?
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Hum Genet 17:883-9. 2009
    ..We also point out some specific steps, along the trustee model, that providers of DTC personal genomics services as well as regulators and policy makers could consider for addressing some of the concerns raised below...
  8. doi request reprint Pharmacogenomics: the importance of accurate phenotypes
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978 Israel
    Pharmacogenomics 11:469-70. 2010
    ..Biobanks created with personalized medicine research in mind should, when possible, have access to donors' clinical data, including detailed disease- and drug-response phenotypes...
  9. doi request reprint Pharmacogenetics education: 10 years of experience at Tel Aviv University
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Pharmacogenomics 11:647-9. 2010
    ..I share here my pharmacogenetics teaching experience over the past decade and look forward to 2020 when - hopefully - the use of pharmacogenetics tools will have become more established in routine clinical care...
  10. pmc Personalized participatory medicine: sharing knowledge and uncertainty
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Genome Med 3:69. 2011
    ..This is illustrated by a case study on treatment choices of breast cancer patients following genotyping for CYP2D6, recently published in Genome Medicine.See research article: http://genomemedicine.com/content/3/10/64...
  11. ncbi request reprint Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education
    D Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Pharmacogenomics J 5:221-5. 2005
    ..We hope that this call would be listened to, and soon followed by beneficial action, ultimately leading to enhanced implementation of personalized medicine into core medical education and practice...
  12. ncbi request reprint Personalized psychiatry: a realistic goal
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Pharmacogenomics 5:213-7. 2004
    ..With the correct focus, realization of some benefits of genetic patient profiling for psychiatric pharmacotherapy might be near, and in due course, lead the way for true personalized psychiatry...
  13. ncbi request reprint Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine
    David Gurwitz
    Department of Human Genetics and Molecular Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Trends Pharmacol Sci 24:122-5. 2003
    ....
  14. ncbi request reprint Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activities
    O Beilin
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978 Israel
    Neuroreport 12:2347-51. 2001
    ..2 mU thrombin/mg brain tissue. The present study offers a simple and reliable method for measuring total thrombin inhibitory activity in brain...
  15. pmc Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain
    David Gurwitz
    Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel
    Eur J Hum Genet 17:991-8. 2009
    ..Further data are needed for determining the cost-effectiveness of routine TPMT testing...
  16. doi request reprint Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways
    Ayelet Morag
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Pharmacogenomics 11:327-40. 2010
    ..We present a novel in vitro method for distinguishing shared versus distinct drug pathways based on comparative cell growth inhibition profiles across a small panel of human lymphoblastoid cell lines (LCLs) from individual donors...
  17. pmc Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene
    Chava Kimchi-Sarfaty
    National Institutes of Health, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4254, USA
    Pharmacogenomics 8:29-39. 2007
    ..The frequencies with which these polymorphisms exist in a population have also been shown to be ethnically related...
  18. ncbi request reprint Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe
    M Elske van den Akker-van Marle
    TNO Netherlands Organization for Applied Scientific Research, Quality of Life, Leiden Delft, The Netherlands
    Pharmacogenomics 7:783-92. 2006
    ..Our analysis indicates that TPMT genotyping should be seriously considered as an integral part of healthcare prior to the initiation of therapy with thiopurine drugs...
  19. ncbi request reprint MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population
    Doron M Behar
    Bruce Rappaport Faculty of Medicine and Research Institute, Technion and Rambam Medical Center, Haifa, Israel
    Eur J Hum Genet 12:355-64. 2004
    ..A genetic bottleneck followed by the recent phenomenon of rapid population growth are likely to have produced the conditions that led to the high frequency of many genetic disease alleles in the Ashkenazi population...
  20. ncbi request reprint A human genome diversity cell line panel
    Howard M Cann
    Science 296:261-2. 2002
  21. doi request reprint Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis
    David Gurwitz
    J Natl Cancer Inst 100:1331; author reply 1332-4. 2008
  22. doi request reprint Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients
    Kenji Nakai
    Iwate Medical University, Department of Laboratory Medicine, Morioka 020 8505, Japan
    Pharmacogenomics 8:713-9. 2007
    ....
  23. ncbi request reprint Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing
    Russ B Altman
    Stanford University, Department of Genetics and Bioengineering, Clark S172, Stanford, CA 94305 5444, USA
    Pharmacogenomics 8:519. 2007
  24. ncbi request reprint Primum non nocere: adverse drug events must be taken seriously
    David Gurwitz
    Pharmacogenomics 8:311-4. 2007
  25. ncbi request reprint From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community
    Felix W Frueh
    Stepoutside Consulting, LLC, Gaithersburg, MD 20878, USA
    Pharmacogenomics 5:571-9. 2004
    ..To effectively move pharmacogenetics into everyday medicine, it is therefore imperative for scientists and teachers in the field to take on the challenge of disseminating pharmacogenetic insights to a broader audience...
  26. ncbi request reprint Personalized medicine: decades away?
    Jeantine E Lunshof
    VU University Medical Center, Section Community Genetics, Department of Clinical Genetics and Human Genetics, EMGO Institute, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Pharmacogenomics 7:237-41. 2006
  27. ncbi request reprint Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations
    Kenji Nakai
    Department of Laboratory Medicine, Iwate Medical University, Morioka 020 8505, Japan
    Life Sci 78:107-11. 2005
    ..85/0.15) and Yemenite Jews (0.849/0.151). Thus, the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) variants were rare in the Japanese population, and showed different frequencies in the four Jewish ethnic groups examined...
  28. ncbi request reprint Response to Sykiotis and Papavassiliou: Professional education in molecular medicine--pharmacogenetics first
    Jeantine E Lunshof
    Trends Mol Med 11:485-6. 2005